Successful Treatment of Severe Atopic Dermatitis and Alopecia Universalis With Upadacitinib in a 29-Year-Old Male Patient

This study found that corticosteroids were the most common treatments for alopecia areata in the USA, but the substantial disease burden suggests a need for more effective options.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

This case report describes a canine with alopecia areata universalis treated with oral ciclosporin, which was associated with hair regrowth, but some areas remained hairless after 17 months.

This abstract reviews the causes and prognosis of alopecia areata but reports no new clinical findings.